“Research Article”
Received August 22, 2016; Accepted January 09, 2017; Published February 11, 2017
http://dx.doi.org/10.18081/2333-5106/017-32-44
Debolina Bokemeyer; Ratna Price; Sarita Saltz; Min Engelman; Johanna Loehrer
Abstract
An overall understanding of signaling through the epidermal growth factor receptor (EGFR) and respective signaling pathways must be elucidated in the context of neutropenic fever conditions. Comprehensive studies can be carried out, with the previous and emerging data, to gain insight into this area. The aim of these future investigations should lead to the development of more effective strategies for treatment and also elevate medical practice to prevent potential future impacts on patients’ quality of life. The epidermal growth factor receptor (EGFR) is a major signaling receptor that activates different pathways, including monocarboxylate transporter (MCT). Earlier, it has been shown that there is a likelihood of reducing the incidence of neutropenic fever in patients who go through hematopoietic stem cell transplantation (HSCT) through the activation of EGFR during routine adjuvant cancer treatment. Although the activation of receptor tyrosine kinases (RTK) in febrile neutropenia is known and documented, investigators still neglect the potential of treating patients with tyrosine kinase receptor inhibitors (TKI). The purpose of this research agenda is to conduct research into this new upcoming emerging field both in the presence and absence of cancer. A diverse and emerging area under investigation, it would eventually facilitate devising effective strategies that might be helpful in minimizing the expected impact of neutropenic fever by activating EGFR, either through new adjuvant cancer immune therapy or through gene-editing possibilities. National and international collaboration between biomedical researchers and doctors involved in basic and clinical care will be available for physicians to provide safe and effective adjuvant care for neutropenic patients. These future innovations will improve the patient’s quality of life.
Keywords: Cancer; Neutropenic fever; EGFR; ErbB-1
References
1. Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015; 13:37. [Abstract/Full-Text]
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341–354. [PubMed]
3. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593–1611. [PubMed]
4. Li KJ, Siao SC, Wu CH. et al. EGF receptor-dependent mechanism may be involved in the Tamm–Horsfall glycoprotein-enhanced PMN phagocytosis via activating Rho family and MAPK signaling pathway. Molecules 2013;19:1328–1343. [Scopus]
5. Vinante F, Rigo A. Heparin-binding EGFR/diphtheria toxin receptor in normal and neoplastic hematopoiesis. Toxins 2013;5:1180–1201. [Scopus]
6. Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012;67:400–408. [PubMed] [Scopus]
7. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 2012;11:S9–19. [PubMed] [Scopus]
8. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23:1672–1679. [PubMed] [Scopus]
9. Funakoshi T, Suzuki M,Tamur K. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. Cancer treatment reviews 2014; 40(0):1221–1229. [Abstract/Full-Text]
10. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013; 35:1282-1303. [PubMed]
11. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the EGFR in cancer: apoptosis takes center stage. Cancer Res 2003; 63:1-5. [PubMed]
12. Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with cetuximab–an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009; 77:124-133. [PubMed]
13. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.J Chemother. in press.
14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol 2011;12: 104–117. [PubMed] [Scopus]
15. Ding L, Getz G, Wheeler DA. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537–540. [PubMed]
16. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012;2: 934–947. [CrossRef] [PubMed]
17. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of EGFR mutations in human glioblastomas. Cancer Res 2000; 60: 1383–1387. [PubMed]
